Facebook Youtube Instagram Linkedin

  • The results are being filtered by the character: M
A B C D E F G H J K L M N O P R S T U W X Y Z
Photo of Gediminas “Gedi” Mainelis Ph.D.
Gediminas “Gedi” Mainelis, Ph.D.
Professor Rutgers University, School of Environmental and Biological SciencesEOHSI – Environmental and Population Health Bio-Sciences

Research Areas

  • Development of aerosol/bioaerosol sampling, control, and generation methods
  • Investigation of aerosol and bioaerosol monitors’ performance
  • Integration of bioaerosol sampling tools with advanced microbiological analysis techniques Aerosol exposure assessment
    Indoor air quality
  • Exposure and health effects of nanoparticles

Research Highlights

  • Investigated the potential release of particles from nanotechnology-based consumer products and showed that their use could result in inhalation exposures to nanoparticles and their agglomerates
  • Developed a novel electrostatics-based collector for biological aerosols where airborne particles could be captured into very small amounts of liquid (5-40 microliters) thus allowing to measure low concentrations of airborne microorganisms.
  • Investigated indoor exposures of young children to airborne contaminants using a novel robotic sampling platform. The research shows that the current exposure assessment methods using stationary samplers may underestimate exposures by a factor of 3.

Scholarly Activities

  • Co-Chair of the “Health-Related Aerosol Working Group” of the American Association for Aerosol Research for 2010-2011.
  • Member, Aerosol Technology Committee, American Industrial Hygiene Association.
  • Member, Stakeholders’ Panel on Agent Detection Assays (SPADA), organized by AOAC International, contracted by the Department of Homeland Security’s Chemical/Biological Research and Development Section (CBRDS)
  • Reviewer for scholarly journals

Recent Publications

Dr. Mainelis’s Publications – Google Scholar

  1. Lu, FT, Laumbach, RJ, Legard, A, Myers, NT, Black, KG, Ohman-Strickland, P, Alimokhtari, S, de Resende, A, Calderón, L, Mainelis, G et al.. Real-World Effectiveness of Portable Air Cleaners in Reducing Home Particulate Matter Concentrations. Aerosol Air Qual Res. 2024;24 (1):. doi: 10.4209/aaqr.230202. PubMed PMID:38618024 PubMed Central PMC11014421
  2. He, R, McAtee, J, Mainelis, G. Potential exposure of adults and children to particles from resuspended nano-enabled consumer sprays. Sci Total Environ. 2024;924 :171459. doi: 10.1016/j.scitotenv.2024.171459. PubMed PMID:38438041
  3. Desai, G, Ramachandran, G, Goldman, E, Esposito, W, Galione, A, Lal, A, Choueiri, TK, Fay, A, Jordan, W, Schaffner, DW et al.. Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate. Environ Sci Technol. 2023;57 (10):4231-4240. doi: 10.1021/acs.est.2c08632. PubMed PMID:36853925 PubMed Central PMC10001433
  4. He, R, Zhang, J, Mainelis, G. Resuspension of particles deposited by nano-enabled consumer sprays: The role of product type, flooring material, and resuspension force. Indoor Air. 2022;32 (11):e13157. doi: 10.1111/ina.13157. PubMed PMID:36437654 PubMed Central PMC9827835
  5. Dillon, KP, Krumins, V, Deshpande, A, Kerkhof, LJ, Mainelis, G, Fennell, DE. Characterization and DNA Stable-Isotope Probing of Methanotrophic Bioaerosols. Microbiol Spectr. 2022;10 (6):e0342122. doi: 10.1128/spectrum.03421-22. PubMed PMID:36409096 PubMed Central PMC9769660
  6. Manibusan, S, Mainelis, G. Passive Bioaerosol Samplers: A Complementary Tool for Bioaerosol Research. A Review. J Aerosol Sci. 2022;163 :. doi: 10.1016/j.jaerosci.2022.105992. PubMed PMID:36386279 PubMed Central PMC9648171
  7. Goldman, E, Choueiri, TK, Mainelis, G, Ramachandran, G, Schaffner, DW. Triethylene Glycol Can Be Predeployed as a Safe Virus-Killing Indoor Air Treatment. J Infect Dis. 2022;226 (11):2040-2041. doi: 10.1093/infdis/jiac394. PubMed PMID:36177834
  8. Myers, NT, Laumbach, RJ, Black, KG, Ohman-Strickland, P, Alimokhtari, S, Legard, A, De Resende, A, Calderón, L, Lu, FT, Mainelis, G et al.. Portable air cleaners and residential exposure to SARS-CoV-2 aerosols: A real-world study. Indoor Air. 2022;32 (4):e13029. doi: 10.1111/ina.13029. PubMed PMID:35481935 PubMed Central PMC9111720
  9. Grogan, SNCM, Han, TT, Mainelis, G. Development and initial testing of an active low-power, ferroelectric film-based bioaerosol sampler. Aerosol Sci Technol. 2022;56 (12):1132-1145. doi: 10.1080/02786826.2022.2128985. PubMed PMID:37168518 PubMed Central PMC10168024
  10. Laumbach, RJ, Mainelis, G, Black, KG, Myers, NT, Ohman-Strickland, P, Alimokhtari, S, Hastings, S, Legard, A, de Resende, A, Calderón, L et al.. Presence of SARS-CoV-2 Aerosol in Residences of Adults with COVID-19. Ann Am Thorac Soc. 2022;19 (2):338-341. doi: 10.1513/AnnalsATS.202107-847RL. PubMed PMID:34762562 PubMed Central PMC8867362
Search PubMed
Photo of Elizabeth G Marshall Ph.D.
Elizabeth G Marshall, Ph.D.
EOHSI – Environmental and Population Health Bio-Sciences
Photo of Bindhu Mathew
Bindhu Mathew
Nurse Case Manager Rutgers UniversityEOHSI-Clinical Research and Occupational Medicine
Naureen Memon, M.D.
Fellow Rutgers UniversityEOHSI – Toxicology
Photo of Zhongyuan “Wheat” Mi M.P.H.
Zhongyuan “Wheat” Mi, M.P.H.
Rutgers UniversityEOHSI – Environmental and Population Health Bio-Sciences
Photo of Joshua Miller Ph.D.
Joshua Miller, Ph.D.
Rutgers UniversitySchool of Environmental and Biological Sciences
Photo of Tamara Minko Ph.D.
Tamara Minko, Ph.D.
Distinguished Professor – Chair, Department of Pharmaceutics Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology

Dr. Tamara Minko is a Professor II and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. She is also a member of the Cancer Institute of New Jersey, Environmental and Occupational Health Sciences Institute. Her current research interests include drug delivery; biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Professor Minko is author and co-author of more than 400 publications (peer-reviewed papers, books and textbook chapters, conference proceedings, patents). Many of her papers are well cited and published in prestigious journals with high impact factors including PNAS, Nature Nanotechnology, Cancer Research, Clinical Cancer Research, Advanced Drug Delivery Review, Journal of Controlled Release, etc. Dr. Minko is a Fellow of the American Association of Pharmaceutical Scientists, elected member of the Board of Scientific Advisors of the Controlled Release Society, recipient of numerous awards, Editor of Pharmaceutical Research, member of editorial board of several scientific journals and a member of Study Sections at NIH, DOD, American Heart Association and other national and international review panels. Her research is supported by grants from NIH, NSF, DOD and other national and international sources.

Research Areas

Biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Ongoing/Recent Research Support

  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 04/01/03 – 07/31/12. NIH/NCI R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular Targeting of Drug Delivery System to Cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination Nanotherapeutic Strategies to Overcome Tumor Drug Resistance.
  • 07/01/09 – 06/30/12. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • Ongoing Research Support:
  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 10/01/09 – 09/31/11. NIH/NCI (ARRA) R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular targeting of drug delivery system to cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination nanotherapeutic strategies to overcome tumor drug resistance.
  • 07/01/09 – 06/30/11. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 09/15/06 – 06/30/11. NIH/NIBIB R01 EB007049, T. Minko – Co- Principal Investigator. Carrier Shape Matters: Filomicelles, Long-circulation, and the EPR effect. (Principal Investigator – Dr. D. Discher, University of Pennsylvania).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • 07/01/10 – 06/30/11. Department of Defense Lung Cancer Research Program W81XWH-10-1-0347, T. Minko Co-Investigator (Principal Investigator – Dr. O. Taratula, Postdoctoral Research Associate working under the supervision of Dr. Minko). Innovative Strategy for Treatment of Lung Cancer: Inhalatory Co-Delivery of Anticancer drugs and siRNA for Suppression of Cellular Resistance.

Research Highlights

  • Nanotechnology based inhalatory treatment of lung cancer
  • Targeted multifunctional approach for treatment of multidrug resistant cancer and prevention of metastases
  • Prevention of cellular hypoxic damage by the suppression of Jun N-Terminal Kinase 1

Scholarly Activities

  • 2010 Member (Elected), Board of Scientific Advisors, Controlled Release Society
  • 2009 Fellow of the American Association of Pharmaceutical Scientists (AAPS)
  • 2008, 2010, 2011 Controlled Release Society Outstanding Pharmaceutical Paper Award
  • 1998 The Jorge Heller Journal of Controlled Release/Controlled Release Society Outstanding Paper Award

Recent Publications

  1. Lee, D, Shen, AM, Shah, M, Garbuzenko, OB, Minko, T. In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer’s Disease Therapy. Int J Mol Sci. 2024;25 (19):. doi: 10.3390/ijms251910357. PubMed PMID:39408684 PubMed Central PMC11476875
  2. Lee, D, Shen, AM, Garbuzenko, OB, Minko, T. Liposomal Formulations of Anti-Alzheimer Drugs and siRNA for Nose-to-Brain Delivery: Design, Safety and Efficacy In Vitro. AAPS J. 2024;26 (5):99. doi: 10.1208/s12248-024-00967-x. PubMed PMID:39231845
  3. Romaniuk-Drapala, A, Skupin-Mrugalska, P, Garbuzenko, O, Hatefi, A, Minko, T. Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells. Cancer Cell Int. 2024;24 (1):285. doi: 10.1186/s12935-024-03469-0. PubMed PMID:39135053 PubMed Central PMC11320834
  4. Minko, T, Taratula, O. Nanomedicine for Women’s Health. Small. 2024;20 (41):e2405178. doi: 10.1002/smll.202405178. PubMed PMID:39032120
  5. Gu, X, Majumder, J, Taratula, O, Kuzmov, A, Garbuzenko, O, Pogrebnyak, N, Minko, T. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog. Int J Mol Sci. 2024;25 (10):. doi: 10.3390/ijms25105545. PubMed PMID:38791582 PubMed Central PMC11122428
  6. Gu, X, Minko, T. Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer. Cancers (Basel). 2024;16 (8):. doi: 10.3390/cancers16081589. PubMed PMID:38672671 PubMed Central PMC11048786
  7. Garbuzenko, OB, Sapiezynski, J, Girda, E, Rodriguez-Rodriguez, L, Minko, T. Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer. Small. 2024;20 (41):e2307462. doi: 10.1002/smll.202307462. PubMed PMID:38342698 PubMed Central PMC11316847
  8. Shen, AM, Malekshah, OM, Pogrebnyak, N, Minko, T. Plant-derived single domain COVID-19 antibodies. J Control Release. 2023;359 :1-11. doi: 10.1016/j.jconrel.2023.05.030. PubMed PMID:37225092 PubMed Central PMC10231691
  9. Gildiz, S, Minko, T. Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer. Pharm Res. 2023;40 (1):123-144. doi: 10.1007/s11095-022-03434-4. PubMed PMID:36376606 PubMed Central PMC9663189
  10. Castellano, GM, Zeeshan, S, Garbuzenko, OB, Sabaawy, HE, Malhotra, J, Minko, T, Pine, SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022;21 (9):1381-1392. doi: 10.1158/1535-7163.MCT-22-0053. PubMed PMID:35732569 PubMed Central PMC9452486
Search PubMed
Kristopher Minsinger, MD
Resident EOHSI-Rutgers UniversityClinical Research and Occupational Medicine
Photo of Dirk F Moore Ph.D.
Dirk F Moore, Ph.D.
Associate Professor Rutgers University, School of Public HealthEOHSI – Environmental and Population Health Bio-Sciences

Recent Publications

  1. Malhotra, J, Chiappori, A, Fujioka, N, Hanna, NH, Feldman, LE, Patel, M, Moore, D, Chen, C, Jabbour, SK. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study. Lung Cancer. 2024;195 :107932. doi: 10.1016/j.lungcan.2024.107932. PubMed PMID:39173229
  2. Allen, WE, Greendyk, JD, Alexander, HR, Beninato, T, Eskander, MF, Grandhi, MS, In, H, Kennedy, TJ, Langan, RC, Maggi, JC et al.. Racial disparities in rates of invasiveness of resected intraductal papillary mucinous neoplasms in the United States. Surgery. 2024;175 (5):1402-1407. doi: 10.1016/j.surg.2024.01.028. PubMed PMID:38423892
  3. Daniel, LC, Venella, KL, Woodard, K, Poliakova, P, Gross, JY, Bercovitz, IN, Moore, D, Barakat, LP, Freedman, JL. Can extending time between vital sign checks improve sleep in hematopoietic stem cell transplant patients? Testing feasibility, acceptability, and preliminary efficacy. Pediatr Blood Cancer. 2024;71 (4):e30832. doi: 10.1002/pbc.30832. PubMed PMID:38197636
  4. Cararo Lopes, E, Sawant, A, Moore, D, Ke, H, Shi, F, Laddha, S, Chen, Y, Sharma, A, Naumann, J, Guo, JY et al.. Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer. Clin Transl Med. 2023;13 (6):e1298. doi: 10.1002/ctm2.1298. PubMed PMID:37317665 PubMed Central PMC10267429
  5. Yashar, C, Khan, AJ, Chen, P, Einck, J, Poppe, M, Li, L, Yehia, ZA, Vicini, FA, Moore, D, Arthur, D et al.. Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial. Pract Radiat Oncol. 2023;13 (4):314-320. doi: 10.1016/j.prro.2023.03.006. PubMed PMID:37140504
  6. Cararo-Lopes, E, Sawant, A, Moore, D, Ke, H, Shi, F, Laddha, S, Chen, Y, Sharma, A, Naumann, J, Guo, JY et al.. Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans. medRxiv. 2023; :. doi: 10.1101/2023.03.09.23287037. PubMed PMID:36945575 PubMed Central PMC10029066
  7. Gulhati, P, Schalck, A, Jiang, S, Shang, X, Wu, CJ, Hou, P, Ruiz, SH, Soto, LS, Parra, E, Ying, H et al.. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4 (1):62-80. doi: 10.1038/s43018-022-00500-z. PubMed PMID:36585453 PubMed Central PMC9925045
  8. Fosko, NK, Gribkova, Y, Krupa, K, Bs, KJ, Moore, D, Chen, C, Potdevin, L, Kumar, S, Eladoumikdachi, F, Kowzun, MJ et al.. The Use of Intraoperative Ultrasound During Breast Conserving Surgery. Clin Breast Cancer. 2023;23 (1):54-59. doi: 10.1016/j.clbc.2022.10.003. PubMed PMID:36319507
  9. Moore, DF, Sleat, DE, Lobel, P. A Method to Estimate the Distribution of Proteins across Multiple Compartments Using Data from Quantitative Proteomics Subcellular Fractionation Experiments. J Proteome Res. 2022;21 (6):1371-1381. doi: 10.1021/acs.jproteome.1c00781. PubMed PMID:35522998
  10. Gazivoda, VP, Kangas-Dick, AW, Greenbaum, AA, Roshal, J, Chen, C, Moore, DF, Langan, RC, Kennedy, TJ, Minerowicz, C, Alexander, HR et al.. Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study. J Surg Res. 2022;277 :131-137. doi: 10.1016/j.jss.2022.04.005. PubMed PMID:35489218
Search PubMed
Photo of Phyllis Morgan
Phyllis Morgan
Rutgers UniversityEOHSI – Clinical Research and Occupational Medicine

170 Frelinghuysen Road, Piscataway, NJ 08854 – 848-445-0200  Fax: 732-445-0131

Facebook Youtube Instagram Linkedin

Copyright © 2021, Rutgers, The State University of New Jersey